Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-281: capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer
NL-OMON52862Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Capivasertib + abiraterone with Placebo + abiraterone (2 arms). Primary endpoint: Radiographic progression-free survival. Started Jan 2021; status: active, not recruiting.
02
Drugs
capivasertibabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52862.